takeda-pharmaceutical-company-limited

Médias

Takeda Presents Additional Data from the EXAMINE Cardiovascular Safety Outcomes Trial at the American College of Cardiology's 63rd Annual Scientific Session

Médias

Takeda Receives Positive CHMP Opinion for Entyvio® (vedolizumab) in Europe for the Treatment of Ulcerative Colitis and Crohn's Disease

Médias

Takeda's New Investigational Drug Vedolizumab Entered Phase 3 Clinical Trials in Japan For the Treatment of Ulcerative Colitis and Crohn's Disease

Médias

Revestive(R) (Teduglutide) Receives European Marketing Authorization for the Treatment of Adults With Short Bowel Syndrome (SBS)

Médias

Takeda Anuncia la Aceptación a Trámite por parte de la EMA de Dos Terapias para Diabetes Tipo 2

Médias

Takeda Announces Acceptance of European Medicines Agency Submissions for Two Fixed-Dose Combination Therapies, Alogliptin and Pioglitazone and Alogliptin and Metformin, for the Treatment of Type 2 Diabetes